- Home
- BODI vs SCYX Comparison
BODI vs SCYX Comparison
Compare BODI & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BODI
- SCYX
- Stock Information
- Founded
- BODI 1998
- SCYX 1999
- Country
- BODI United States
- SCYX United States
- Employees
- BODI N/A
- SCYX N/A
- Industry
- BODI Industrial Machinery/Components
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- BODI Industrials
- SCYX Health Care
- Exchange
- BODI Nasdaq
- SCYX Nasdaq
- Market Cap
- BODI 25.4M
- SCYX 28.5M
- IPO Year
- BODI N/A
- SCYX 2014
- Fundamental
- Price
- BODI $4.15
- SCYX $0.71
- Analyst Decision
- BODI Strong Buy
- SCYX
- Analyst Count
- BODI 3
- SCYX 0
- Target Price
- BODI $10.67
- SCYX N/A
- AVG Volume (30 Days)
- BODI 23.6K
- SCYX 142.0K
- Earning Date
- BODI 08-05-2025
- SCYX 08-07-2025
- Dividend Yield
- BODI N/A
- SCYX N/A
- EPS Growth
- BODI N/A
- SCYX N/A
- EPS
- BODI N/A
- SCYX N/A
- Revenue
- BODI $371,113,000.00
- SCYX $2,630,000.00
- Revenue This Year
- BODI N/A
- SCYX $463.61
- Revenue Next Year
- BODI N/A
- SCYX $310.80
- P/E Ratio
- BODI N/A
- SCYX N/A
- Revenue Growth
- BODI N/A
- SCYX N/A
- 52 Week Low
- BODI $3.38
- SCYX $0.66
- 52 Week High
- BODI $8.71
- SCYX $2.29
- Technical
- Relative Strength Index (RSI)
- BODI 50.21
- SCYX 38.69
- Support Level
- BODI $3.75
- SCYX $0.67
- Resistance Level
- BODI $4.43
- SCYX $0.75
- Average True Range (ATR)
- BODI 0.28
- SCYX 0.04
- MACD
- BODI 0.03
- SCYX 0.00
- Stochastic Oscillator
- BODI 53.31
- SCYX 33.06
About BODI The Beachbody Company Inc. Class A Common Stock
The Beachbody Co Inc is a health and wellness platform providing fitness, nutrition and stress-reducing programs to its customers. The product offerings of the company include Digital Subscriptions, Nutritional Products, and Connected Fitness Products. It earns the majority of its revenue from the United States. The company operates and manages its business in one operating segment. Majority of revenue is through Digital.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.